Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation

Read full text Summarise with VIRAT
Authors: Mojmír Hlavatý, Jan Březina, Pavel Wohl, István Módos, Lukáš Bajer, Ondřej Fabián, Andrea Vajsová, Tomáš Hucl, Pavel Drastich
Cited by: 0
References: 31

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Liver transplantation (LT) is the most effective treatment for the advanced stages of primary sclerosing cholangitis (PSC). However, up to 30% of patients develop recurrence of PSC (rPSC), which negatively affects graft and patient outcomes. Given the heterogeneous nature of PSC, patients undergo LT either due to end-stage liver disease (ESLD) or to symptoms that significantly reduce quality of life (non-ESLD), such as recurrent bacterial cholangitis or refractory pruritus. However, it remains unclear whether these indicators influence post-LT outcomes. AIM To compare post-LT outcomes between PSC recipients with ESLD and non-ESLD indications, and identify rPSC and graft failure risk factors. METHODS This single-center retrospective study comprised 131 adult LT recipients for PSC (including PSC/autoimmune overlap). Patients were grouped by listing indication for comparison of ESLD vs non-ESLD. ESLD was defined as model for ESLD score ≥ 15 and Child-Pugh score ≥ 8, or ≥ 1 sign of decompensated cirrhosis. Time-to-event outcomes were analyzed using Kaplan-Meier and Cox models with time-updated covariates. RESULTS No significant difference was found in the incidence of rPSC, graft survival, or overall survival between patients indicated for LT for ESLD and those with non-advanced symptomatic disease. Cytomegalovirus infection (hazard ratio [HR] = 2.16; 95% confidence interval [CI]: 1.05-4.46), acute cellular rejection (ACR) (HR = 3.95; 95%CI: 1.44-10.8), and length of hospitalization after LT (HR = 1.02; 95%CI: 1.01-1.04) were significantly associated with risk of rPSC. In addition, multiple episodes of ACR (HR = 4.93; 95%CI: 1.22-19.9) and the length of hospitalization after LT (HR = 1.04; 95%CI: 1.01-1.06) were significantly associated with graft failure. CONCLUSION Patients with PSC with advanced liver cirrhosis before LT did not have worse post-transplant outcomes than those without ESLD. Cytomegalovirus infection, ACR, and prolonged hospitalization after LT were associated with worse outcomes after LT in PSC.

Fields of Study & Subjects

Liver Diseases and Immunity Organ Transplantation Techniques and Outcomes Transplantation: Methods and Outcomes

Publication details

Journal / source
World Journal of Hepatology
Volume
18
Issue
3
Publication date
26 March 2026
Language
EN